Antibody recognizing folate receptors alpha and beta
US-2015343088-A1 · Dec 3, 2015 · US
Flagellin related polypeptides and uses thereof
US9827289B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9827289-B2 |
| Application number | US-201615254695-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 1, 2016 |
| Priority date | Dec 22, 2004 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating apoptosis-mediated tissue damage in a patient in need thereof comprising administering to said patient a composition comprising a pharmaceutically effective amount of a flagellin polypeptide, wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 8, 10, 12, 30, 32, 34, 36, 38, 40, 42, and 44, and wherein the apoptosis is attributable to a cellular stress. 2. The method of claim 1 , wherein the cellular stress is due to radiation. 3. The method of claim 1 , wherein the composition is administered in combination with a radioprotectant. 4. The method of claim 3 , wherein the radioprotectant is an antioxidant. 5. The method of claim 4 , wherein the antioxidant is selected from the group consisting of amifostine and vitamin E. 6. The method of claim 3 , wherein the radioprotectant is a cytokine. 7. The method of claim 6 , wherein the cytokine is a stem cell factor. 8. The method of claim 3 , wherein the radioprotectant is a growth factor. 9. The method of claim 8 , wherein the growth factor is keratinocyte growth factor. 10. The method of claim 3 , wherein the radioprotectant is a steroid. 11. The method of claim 10 , wherein the steroid is 5-androstenediol. 12. The method of claim 3 , wherein the radioprotectant is ammonium trichloro(dioxoethylene-O,O′)tellurate. 13. The method of claim 1 , wherein the cellular stress is due to radiation. 14. The method of claim 1 , wherein the composition is administered prior to, together with, or after radiation. 15. The method of claim 13 , wherein the radiation is the one that occurs in cancer radiotherapy.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9827289B2 cover?
- The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
- Who is the assignee on this patent?
- Cleveland Clinic Found
- What technology area does this patent fall under?
- Primary CPC classification A61K38/164. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).